Oncology - Sanofi
WEBOncology. A cancer diagnosis carries incredible burdens. That’s why we pursue new therapies, work to help expand access to medicines, provide support, and learn from patients every day. At Sanofi, we are dedicated to delivering cancer care that fits in the lives of people living with this disease.
Sanofi Oncology | Working to Improve the Lives of People with Cancer
WEBOur ambition is to develop both backbone therapies and potential first-in-class medicines for difficult-to-treat cancer types. Whether it’s pursuing scientific discoveries, researching breakthrough oncology medicines, or seeking answers for patients, Sanofi never settles.
Our Commitment to Oncology - Advancing Cancer Care | Sanofi
WEBDiscover Sanofi's oncology commitment, delivering oncology and immuno-oncology drugs to transform cancer care around the globe to help improve outcomes.
Sanofi Oncology | Working to Improve the Lives of People with Cancer
WEBWe are advancing transformative therapies in a variety of difficult-to-treat cancers. Learn more about our commitment to the oncology community.
Oncology R&D: Sanofi's Path to Cancer Treatment | Sanofi
WEBOur immuno-oncology teams are working on ways to boost the immune system to better detect and attack tumors. And our molecular oncology teams are designing powerful precision drugs to either destroy cancer cells or activate immune cells locally.
Oncology - Sanofi
WEBOur modalities include AI-driven drug discovery and design, antibody-drug conjugates, natural killer (NK) cell therapies, T-cell and NK-cell engagers, soluble TCRs, and gene therapies, to name just a few.
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patients.
FDA Approves Sarclisa, Sanofi's First Cancer Drug in 10 Years ...
WEBMar 3, 2020 · The French drugmaker Sanofi has officially re-entered oncology, as the Food and Drug Administration approved the multiple myeloma treatment Sarclisa on Monday. Sanofi's last new cancer drug was...
Sanofi wins US approval for myeloma drug key to its cancer …
WEBPublished March 2, 2020. Ned Pagliarulo Lead Editor. Sanofi/Flickr. Dive Brief: The Food and Drug Administration on Monday approved a new drug for multiple myeloma, clearing Sanofi’s Sarclisa for market at a time when drugmakers are racing to develop new types of therapies for the blood cancer.
Our Products and Resources | Sanofi USA
WEBSanofi is a diversified global healthcare leader, focused on developing products that meet the health needs of people. We have extensive lines of prescription medicines and vaccines, as well as consumer health products. Prescription Products. Vaccine Products.
- Some results have been removed